122 related articles for article (PubMed ID: 1777378)
1. Pharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis.
Spreux-Varoquaux O; Doll J; Dutot C; Grandjean N; Cordonnier P; Pays M; Andrieu J; Advenier C
Br J Clin Pharmacol; 1991 Sep; 32(3):399-401. PubMed ID: 1777378
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of molsidomine and of its active metabolite, SIN-1 (or linsidomine), in the elderly.
Spreux-Varoquaux O; Ulmer B; Cordonnier P; Forestier A; Pays M; Ducreuzet C; Advenier C
Fundam Clin Pharmacol; 1991; 5(6):549-56. PubMed ID: 1955198
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients.
Rames A; Poirier JM; LeCoz F; Midavaine M; Lecocq B; Grange JD; Poupon R; Cheymol G; Jaillon P
Clin Pharmacol Ther; 1990 Mar; 47(3):354-9. PubMed ID: 2178853
[TBL] [Abstract][Full Text] [Related]
4. Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers.
Wildgrube HJ; Ostrowski J; Chamberlain J; Gärtner W; Stockhausen H
Arzneimittelforschung; 1986 Jul; 36(7):1129-33. PubMed ID: 3768083
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of molsidomine.
Rosenkranz B; Winkelmann BR; Parnham MJ
Clin Pharmacokinet; 1996 May; 30(5):372-84. PubMed ID: 8743336
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of glafenine and glafenic acid in patients with cirrhosis, compared to healthy volunteers.
Vermerie N; Kusielewicz D; Tod M; Nicolas P; Perret G; Fauvelle F; Petitjean O
Fundam Clin Pharmacol; 1992; 6(4-5):197-203. PubMed ID: 1358775
[TBL] [Abstract][Full Text] [Related]
7. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis.
Vinel JP; Monnin JL; Combis JM; Calés P; Desmorat H; Pascal JP
Hepatology; 1990 Feb; 11(2):239-42. PubMed ID: 2307402
[TBL] [Abstract][Full Text] [Related]
9. A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: correlation between efficacy and over time plasma concentrations.
Messin R; Fenyvesi T; Carreer-Bruhwyler F; Crommen J; Chiap P; Hubert P; Dubois C; Famaey JP; Géczy J
Eur J Clin Pharmacol; 2003 Jul; 59(3):227-32. PubMed ID: 12734607
[TBL] [Abstract][Full Text] [Related]
10. Systemic and splanchnic hemodynamic effects of molsidomine in rats with carbon tetrachloride-induced cirrhosis.
Desmorat H; Vinel JP; Lahlou O; Pipy B; Badia P; Cales P; Combis JM; Souqual MC; Pascal JP
Hepatology; 1991 Jun; 13(6):1181-4. PubMed ID: 2050332
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of perindopril in patients with liver cirrhosis.
Thiollet M; Funck-Brentano C; Grangé JD; Midavaine M; Resplandy G; Jaillon P
Br J Clin Pharmacol; 1992 Mar; 33(3):326-8. PubMed ID: 1576057
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamics, tolerability, and pharmacokinetics of linsidomine (SIN-1) infusion during the acute phase of uncomplicated myocardial infarction.
Foucher-Lavergne A; Kolsky H; Spreux-Varoquaux O; Delonca J; Beaufils P
J Cardiovasc Pharmacol; 1993 Dec; 22(6):779-84. PubMed ID: 7509893
[TBL] [Abstract][Full Text] [Related]
13. [The effect of molsidomine on portal and cardiac hemodynamics in liver cirrhosis].
Hüppe D; Jäger D; Tromm A; Tunn S; Barmeyer J; May B
Dtsch Med Wochenschr; 1991 May; 116(22):841-5. PubMed ID: 2036943
[TBL] [Abstract][Full Text] [Related]
14. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alcoholic cirrhosis.
Lill JS; O'Sullivan T; Bauer LA; Horn JR; Carithers R; Strandness DE; Lau H; Chan K; Thakker K
J Clin Pharmacol; 2000 Mar; 40(3):250-7. PubMed ID: 10709153
[TBL] [Abstract][Full Text] [Related]
16. Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis.
Cardey J; Silvain C; Bouquet S; Breux JP; Becq-Giraudon B; Fourtillan JP; Beauchant M
Eur J Clin Pharmacol; 1987; 33(5):469-72. PubMed ID: 3480805
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of linsidomine (SIN 1) after single and multiple intravenous short infusions in patients with renal insufficiency.
Sennesael J; Verbeelen D; Degré S; Unger P; Stolear JC; Ostrowski J; von Hattingberg HM; Gaertner W
Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):533-41. PubMed ID: 8294165
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the lower esophageal sphincter pressure after oral molsidomine by sydnonimine plasma concentrations.
Stoschus B; Fernandez I; Heller J; Neubrand M; Sauerbruch T
Hepatogastroenterology; 1999; 46(26):933-7. PubMed ID: 10370642
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and ascitic fluid penetration of piperacillin in cirrhosis.
Hary L; Smail A; Ducroix JP; Baillet J; Andrejak M
Fundam Clin Pharmacol; 1991; 5(9):789-95. PubMed ID: 1794834
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of paroxetine in patients with cirrhosis.
Dalhoff K; Almdal TP; Bjerrum K; Keiding S; Mengel H; Lund J
Eur J Clin Pharmacol; 1991; 41(4):351-4. PubMed ID: 1839532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
